CC
NPCE icon

Centiva Capital’s Neuropace NPCE Stock Holding History

Centiva Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,857
Closed -$177K – 1603
2025
Q2 		$177K Buy
+15,857
New +$198K ﹤0.01% 1358

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Centiva Capital's NPCE Position: Q3 2025 in Review

Centiva Capital sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 15,857 shares — an estimated $177K sold.

Centiva Capital first reported a position in NPCE in Q2 2025 and held it in 1 quarter. The position peaked at $177K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Centiva Capital reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 15,857 Neuropace shares in Q3 2025, an estimated $177K.
  • Centiva Capital first reported a position in Neuropace in Q2 2025 and held it in 1 quarter.
  • Centiva Capital's Neuropace position peaked at $177K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.